Search Images Maps Play YouTube News Gmail Drive More »
Settings | Sign in

Hepatocellular carcinoma

Scientists debate role of AAV in causing hepatocellular carcinoma - ‎May 27, 2016‎
Liver cancer can be triggered by mutations in cancer driver genes resulting from the insertion of adeno-associated virus (AAV) vectors used to deliver therapeutic genes, although this tumor-inducing role of AAV remains highly controversial.

High Rate of Hepatocellular Carcinoma Recurrence Found in Patients With Hepatitis C Treated With Direct-acting ...

Cancer Therapy Advisor - ‎May 27, 2016‎
Patients with hepatitis C virus (HCV) who are being treated with direct-acting antiviral treatments (DAAs) and who have been successfully treated for hepatocellular carcinoma (HCC) have a high rate of HCC recurrence, according to a retrospective cohort ...

Targeted treatment for liver cancer under way

Science Daily - ‎May 24, 2016‎
The study found that mouse and human liver cancer in which the function of the protein p53 is disturbed or inhibited is dependent on the interaction between the Aurora kinase A (AURKA) and MYC proteins.

Chemoembolization in Hepatocellular Carcinoma

OncLive - ‎May 16, 2016‎
The liver has a dual blood supply, and it appears to be that cancer cells are always finicky. They love to live on arterial blood supply.

Fatal hepatocellular carcinoma presenting with oral metastasis in a patient with synchronic primary malignancies of ...

UroToday - ‎May 25, 2016‎
Hepatocellular carcinoma (HCC) is the most frequent type of liver cancer and its occurrence in the oral cavity as a metastatic neoplasm is a rare event.

BRIEF-OSE Pharma and Effimune announce non-interventional study in hepatocellular carcinoma

Reuters - ‎May 19, 2016‎
May 19 Orphan Synergy Europe Pharma SA : * Ose Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program Source text for Eikon: Further company coverage: (Gdynia ...

New report shares details about the Opportunity Analyzer: Hepatocellular Carcinoma – Opportunity Analysis and ... (blog) - ‎May 16, 2016‎
ResearchMoz_Edit_250x2505 Researchmoz added Most up-to-date research on “OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024” to its huge collection of research reports.

TRACON Pharma Begins Dosing in Phase 1b/2 Trial on Hepatocellular Carcinoma Treatment (NASDAQ:TCON)

Sonoran Weekly Review - ‎May 18, 2016‎
TRACON Pharmaceuticals (NASDAQ:TCON) said after hours Wednesday it initiated dosing in a Phase 1b/2 trial evaluating TRC105 in combination with Nexavar as a treatment for patients with hepatocellular carcinoma. The biopharmaceutical firm noted that ...

OSE Pharma and Effimune Announce the Launch of a Non-Interventional Study in Hepatocellular Carcinoma under a ...

Business Wire (press release) - ‎May 19, 2016‎
This collaborative research program, called MDScan (Myeloid-Derived Suppressor Cells Analysis), was selected by the French National Cancer Institute after a competitive process.

Researchers Identify Potential Biomarker For Liver Cancer

Asian Scientist Magazine - ‎May 27, 2016‎
AsianScientist (May 27, 2016) - Researchers in China have discovered that the enzyme dimethylglycine dehydrogenase (DMGDH) is down-regulated in both hepatocellular carcinoma (HCC) by over 65 percent, according to the expression of 50 pair of ...

Does AAV-based gene delivery cause liver cancer? The debate heats up

EurekAlert (press release) - ‎May 26, 2016‎
Recently published evidence of AAV-associated hepatocellular carcinoma was previously re-examined in Human Gene Therapy, and a new article in the Journal, published by Mary Ann Liebert, Inc., publishers, strongly challenges the re-interpreted data.

High levels of protein p62 predict liver cancer recurrence

Science Daily - ‎May 19, 2016‎
"By defining factors that allow liver cells to progress from pre-cancer to cancer, we were able to find one -- p62 -- that we can also use to predict a liver cancer patient's outcome following full removal of a previous liver tumor," said co-senior ...
See realtime coverage

Study Finds Blacks More Likely to Die From Liver Cancer - ‎May 23, 2016‎
Black patients diagnosed with liver cancer were more likely to die and less likely to receive lifesaving transplants than white patients, researchers reported Monday.

NM Hospital successfully resects a liver in Navi Mumbai

Times of India - ‎May 27, 2016‎
His investigations confirmed the mass in his right lobe to be hepatocellular carcinoma (liver cancer). "The incidences of hepatocellular carcinoma in females is 2.1 per cent while in males it is 0.7 to 7 per cent which has increased four times due to ...

New Study Highlights Potential Cost Savings When Using Yttrium-90 Glass Microspheres for Treatment of ...

PR Newswire (press release) - ‎May 26, 2016‎
Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

Liver cancer recurrence may be predictable from protein levels

Medical News Today - ‎May 23, 2016‎
They confined their investigation to hepatocellular carcinoma, the most common form of adult liver cancer. The researchers gave each sample a grade from 0-3, depending on the average number of protein aggregates that tested positive for p62.
See realtime coverage

Racial disparities found in liver cancer survival rates

EurekAlert (press release) - ‎May 23, 2016‎
San Diego, CA (May 23, 2016) -- Black patients diagnosed with hepatocellular carcinoma (HCC), the most common liver cancer, had a 33 percent increased risk of death compared to non-Hispanic whites. They also were far less likely to receive life-saving ...

OS comparable between Dovitinib, Nexavar for advanced HCC

Healio - ‎May 27, 2016‎
“In this randomized phase 2 study, Dovitinib activity was not greater than that of sorafenib as frontline therapy in Asian-Pacific patients with advanced [hepatocellular carcinoma],” Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital ...

Blacks Have Reduced Survival After Diagnosis of Liver Cancer (blog) - ‎May 24, 2016‎
Dr. Jones: This study reviewed 999 patients diagnosed with hepatocellular carcinoma in a diverse American population over the past ten years.

OSE Pharma and Effimune launch liver cancer study

The Pharma Letter (registration) - ‎May 20, 2016‎
Soon-to-merge French biotechs OSE Pharma (Euronext Paris :OSE) and Effimune have launched a hepatocellular carcinoma (primary liver cancer) study under a private-public collaborative program. The MDScan (Myeloid-Derived Suppressor Cells Analysis) ...